COMPASS Pathways (NASDAQ:CMPS - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.04, Zacks reports. During the same quarter last year, the firm earned ($0.67) EPS.
COMPASS Pathways Stock Down 0.2 %
NASDAQ CMPS traded down $0.01 on Friday, reaching $4.75. The company had a trading volume of 2,081,860 shares, compared to its average volume of 874,967. The firm has a market capitalization of $324.85 million, a PE ratio of -2.16 and a beta of 2.29. The firm has a 50-day moving average of $6.61 and a 200-day moving average of $7.04. COMPASS Pathways has a 1 year low of $4.05 and a 1 year high of $12.75. The company has a debt-to-equity ratio of 0.13, a current ratio of 12.03 and a quick ratio of 12.03.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently commented on CMPS shares. HC Wainwright lowered their price objective on COMPASS Pathways from $120.00 to $60.00 and set a "buy" rating for the company in a research report on Friday. Royal Bank of Canada cut their target price on COMPASS Pathways from $23.00 to $18.00 and set an "outperform" rating on the stock in a research report on Friday. Canaccord Genuity Group cut their price objective on COMPASS Pathways from $50.00 to $48.00 and set a "buy" rating on the stock in a report on Friday, August 2nd. Maxim Group decreased their target price on COMPASS Pathways from $22.00 to $12.00 and set a "buy" rating for the company in a report on Friday. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of COMPASS Pathways in a report on Monday, September 9th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $30.67.
Check Out Our Latest Research Report on COMPASS Pathways
Insider Transactions at COMPASS Pathways
In other COMPASS Pathways news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of the business's stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $6.05, for a total value of $16,093,000.00. Following the transaction, the insider now owns 6,905,774 shares in the company, valued at $41,779,932.70. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 4.25% of the company's stock.
About COMPASS Pathways
(
Get Free Report)
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.
Featured Articles
Before you consider COMPASS Pathways, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and COMPASS Pathways wasn't on the list.
While COMPASS Pathways currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
